|
3 Companies |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
0 Trials |
|
18 News |
|
- | Trial completion: Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review (clinicaltrials.gov) - Sep 28, 2018
P=N/A, N=25, Completed, Sponsor: Stanford University
Recruiting --> Completed
- Bylvay (odevixibat) / Ipsen
New P1 trial: An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects (clinicaltrials.gov) - Mar 16, 2017
P1, N=6, Completed, Sponsor: Albireo
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial completion: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Jan 17, 2017
P2, N=36, Completed, Sponsor: Shire
Recruiting --> Completed Active, not recruiting --> Completed
- ||| cholestyramine (A3384) / Ipsen, Bylvay (odevixibat) / Ipsen
New P1 trial, Combination therapy, Monotherapy: A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 (clinicaltrials.gov) - Nov 14, 2016
P1, N=94, Completed, Sponsor: Albireo
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment closed: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Sep 2, 2016
P2, N=36, Active, not recruiting, Sponsor: Shire
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment change, Trial primary completion date: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Jan 19, 2016
P2, N=36, Recruiting, Sponsor: Shire
Recruiting --> Active, not recruiting N=24 --> 36 | Trial primary completion date: Mar 2016 --> Oct 2016
- Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial primary completion date: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Sep 25, 2015
P2, N=24, Recruiting, Sponsor: Shire
N=24 --> 36 | Trial primary completion date: Mar 2016 --> Oct 2016 Trial primary completion date: Aug 2015 --> Mar 2016
- | Trial completion: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease (clinicaltrials.gov) - Mar 19, 2015
P=N/A, N=30, Completed, Sponsor: Lumena Pharmaceuticals, Inc.
Trial primary completion date: Aug 2015 --> Mar 2016 Recruiting --> Completed
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial completion: IMAGO: Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (clinicaltrials.gov) - Mar 19, 2015
P2, N=20, Completed, Sponsor: Lumena Pharmaceuticals, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment closed, Trial primary completion date: IMAGO: Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (clinicaltrials.gov) - Dec 5, 2014
P2, N=18, Active, not recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment open, Trial initiation date, Trial primary completion date: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Nov 13, 2014
P2, N=24, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Nov 2014 | Trial primary completion date: Dec 2014 --> Aug 2015
- Trial primary completion date: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=30, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Nov 2014 | Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: Aug 2014 --> Nov 2014
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial initiation date: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Jul 15, 2014
P2, N=24, Not yet recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Trial primary completion date: Aug 2014 --> Nov 2014 Initiation date: Mar 2014 --> Aug 2014
- Enrollment open: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=30, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Initiation date: Mar 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- Clinical: Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease (clinicaltrials.gov) - May 4, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
New P2 trial: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Feb 5, 2014
P2, N=24, Not yet recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment open: IMAGO: Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (clinicaltrials.gov) - Aug 13, 2013
P2, N=18, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
New P2 trial: IMAGO: Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (clinicaltrials.gov) - Jul 17, 2013
P2, N=18, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.